Intervention vs Control Group: Number Suspected/Diagnosed With Rifampin-resistant TB
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
Measures 6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note | Source |
|---|---|---|---|---|---|---|
| Risk in group 1 | 0.000355 | 0.0000973 | 0.00129 | wilson | ClinicalTrials.gov | |
| Risk in group 2 | 0.000961 | 0.000411 | 0.00225 | wilson | ClinicalTrials.gov | |
| Risk difference, group 1 minus group 2 | -0.000607 | -0.00192 | 0.000481 | newcombe hybrid score | ClinicalTrials.gov | |
| Risk ratio, group 1 over group 2 | 0.369 | 0.0716 | 1.9 | log | ClinicalTrials.gov | |
| Odds ratio, group 1 over group 2 | 0.369 | 0.0715 | 1.9 | log | ClinicalTrials.gov | |
| Number needed to treat, for one fewer participant with the outcome on Intervention than on Control Group | 1,650 | from the risk difference interval | the interval includes no difference | ClinicalTrials.gov |
Groups 2
Group 2 names the comparator: control.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code | Source |
|---|---|---|---|---|---|---|
| Group 1 | Intervention | Onsite molecular testing for TB with GeneXpert + process redesign to facilitate same-day TB diagnosis and treatment + performance feedback~GeneXpert: Onsite molecular testing with GeneXpert as a replacement for microscopy~Process re-design: Research and Uganda NTLP staff will engage health center staff in a discussion of how to re-organize clinical, laboratory and pharmacy services to enable same-day TB diagnosis and treatment.~Performance Feedback: Feedback of TB diagnostic evaluation quality indicators to health center staff | 2 | 5,637 | OG001 | ClinicalTrials.gov |
| Group 2 | Control Group | Onsite ZN or LED fluorescence microscopy + hub-based GeneXpert testing per existing protocols | 5 | 5,201 | OG000 | ClinicalTrials.gov |
Outcome 5
| Field | Value | Source |
|---|---|---|
| Type | SECONDARY | ClinicalTrials.gov |
| Title | Number Suspected/Diagnosed With Rifampin-resistant TB | ClinicalTrials.gov |
| Description | Effectiveness outcome. | ClinicalTrials.gov |
| Time frame | Within 6 months of presentation to the health center for tuberculosis evaluation | ClinicalTrials.gov |
| Population | The data analyzed included all adult patients in the target population. Those with rifampin-resistant tuberculosis, extrapulmonary tuberculosis and/or missing age data were excluded from the trial population. Therefore, the number of participants analyzed for this measure differs from other parts of the record. | ClinicalTrials.gov |
Trial 8
| Field | Value | Source |
|---|---|---|
| Title | GeneXpert Performance Evaluation for Linkage to Tuberculosis Care | ClinicalTrials.gov |
| NCT number | NCT03044158 | ClinicalTrials.gov |
| Phases | NA | ClinicalTrials.gov |
| Conditions | Tuberculosis, Pulmonary, Rifampicin Resistant Tuberculosis | ClinicalTrials.gov |
| Interventions | GeneXpert I, Process re-design, Performance Feedback | ClinicalTrials.gov |
| Lead sponsor | University of California, San Francisco | ClinicalTrials.gov |
| Results first posted | 2025-02-18 | ClinicalTrials.gov |
| Results on ClinicalTrials.gov | https://clinicaltrials.gov/study/NCT03044158?tab=results | ClinicalTrials.gov |
Source 4
| Field | Value | Source |
|---|---|---|
| Release | trial-comparisons-2026-03-23-0.1.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57 | ClinicalTrials.gov |
| AACT copy | 2026-03-23 | ClinicalTrials.gov |
| Tables read | outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet | ClinicalTrials.gov |
Release trial-comparisons-2026-03-23-0.1.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.